New Collaboration Aims to Advance Cell Therapy for Autoimmune Diseases Like Lupus
Verily and Kyverna Therapeutics are working together to identify new biomarkers and create novel clinical trial design and execution for autoimmune diseases such as lupus. The multi-year collaboration brings together precision health technology and cell therapy engineering to uncover the biology behind why the body resets immunity through CAR-T cell therapy.
In the first phase of the new partnership, Verily will identify biomarkers indicating response to Kyverna’s KYV-101 therapy, which is currently in Phase 1 trial in the US and Europe for refractory lupus nephritis (lupus-related kidney disease in which people do not respond to recommended treatment or quickly relapse after remission).
Using participant-centered study design that draws broader data from real-world settings and trial sites, the partnership will also bring new and reframed evidence or understanding of the biology. Therapies targeting the needs of people with autoimmune diseases and treated with CAR-T cell therapy will also be developed.
Continue to follow the Lupus Foundation of America for developments stemming from this collaboration, as well as other news on lupus drug developments and clinical trials.